Lake Street lowered the firm’s price target on P3 Health Partners (PIII) to $12.50 from $20 and keeps a Buy rating on the shares. Though Q3 aEBITDA results were “disappointing,” P3 is “making progress, even if it is not yet evident in reported results,” which should point to a much-improved 2026, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PIII:
- P3 Health Partners Earnings Call Reveals Growth Amid Challenges
- P3 Health Partners Faces Financial Challenges: Hold Rating Amidst Uncertain Profitability Timeline
- P3 Health Partners Reports Q3 2025 Financial Results
- Cautious Outlook for P3 Health Partners Amid EBITDA Challenges and Capital Needs
- P3 Health Partners Forms New MSO with Commonwealth